

**MEDICINSKI
FAKULTET**

Adresa: Kruševac bb
81000 PODGORICA
CRNA GORA
Tel: +382 20 246 651
Fax: +382 20 243 842
url: www.ucg.ac.me/medf
E-mail: infomedf@ac.me



**MEDICAL
FACULTY**

Address: Kruševac bb
81000 PODGORICA
MONTENEGRO
Phone: +382 20 246 651
Fax: +382 20 243 842
url: www.ucg.ac.me/medf
E-mail: infomedf@ac.me

Broj: 1164/8-1
Podgorica, 11.09.2023. godine

**Univerzitet Crne Gore
Odbor za doktorske studije
n/r predsjedniku – prof. dr Borisu Vukićeviću**

Poštovani,

U prilogu akta dostavljamo Predlog odluke Vijeća Medicinskog fakulteta broj: 1164/8 od 07.09.2023. godine, o imenovanju Komisije za ocjenu prijave doktorske disertacije kandidata dr med Marka Vukovića, na dalje postupanje.

S poštovanjem.

**MEDICINSKI FAKULTET
VF DEKANA,**
Prof. dr Miodrag Radunović



UNIVERZITET CRNE GORE
MEDICINSKI FAKULTET
Broj: 1164/8
Podgorica, 07.09.2023. godine

Na osnovu člana 64 Statuta Univerziteta Crne Gore, člana 32 a Pravila doktorskih studija (Bilten UCG broj:513/20 i 561/22), Inicijalnog predloga Komisije za doktorske studije broj: 975/1 od 18.07.2023. godine, Vijeće Medicinskog fakulteta u Podgorici, na sjednici održanoj 07.09.2023. godine, donijelo je

ODLUKU

I

Predlažemo Odboru za doktorske studije, sastav Komisije za ocjenu prijave doktorske disertacije, pod nazivom "Biomarkeri kod karcinoma beške: Kliničko-patološki i prognostički značaj ekspresije Ki-67" kandidata dr med Marka Vukovića i to:

1. Prof. dr Filip Vukmirović, redovni profesor Medicinskog fakulteta Univerziteta Crne Gore, predsjednik
2. Prof. dr Miodrag Aćimović, redovni profesor Medicinskog fakulteta Univerziteta u Beogradu, mentor -član
3. Prof. dr Vladimir Todorović, redovni profesor Medicinskog fakulteta Univerziteta Crne Gore –član;

II

Prijava teme doktorske disertacije kandidata broj: 975 od 06.07.2023. godine i Predlog sastava Komisije za ocjenu prijave doktorske disertacije, se dostavlja Odboru za doktorske studije, na saglasnost.

OBRAZLOŽENJE

Dr med Marko Vuković, podnio je Medicinskom fakultetu, Prijavu teme doktorske disertacije pod nazivom: "Biomarkeri kod karcinoma beške : Kliničko-patološki i prognostički značaj ekspresije Ki-67". (Broj Prijave: 975 od 06.07.2023.godine).

Komisija za doktorske studije Medicinskog fakulteta, na sjednici održanoj dana 18.07.2023.godine, nakon razmatranja formalnih uslova za prijavu teme doktorske disertacije sa stanovišta neophodnih podataka, a poštujući princip kompetentnosti, inicirala je prema Vijeću Medicinskog fakulteta, sastav Komisije za ocjenu prijave doktorske disertacije. (Inicijalni prijedlog Komisije za doktorske studije broj: 975/1 od 18.07.2023.godine.)

Vijeće Medicinskog fakulteta na sjednici održanoj 07.09.2023. godine, u skladu sa članom 32 a Pravila doktorskih studija, utvrdilo je predlog sastava Komisije za ocjenu prijave doktorske disertacije kako je navedeno u dispozitivu ove Odluke.

Prijava teme doktorske disertacije broj: 975 od 06.07.2023. godine i Predlog sastava Komisije za ocjenu prijave doktorske disertacije, se dostavljaju Odboru za doktorske studije na dalju proceduru saglasno Pravilima doktorskih studija.

VIJEĆE MEDICINSKOG FAKULTET
PREDSJEDAVAJUĆI,

Prof. dr Miodrag Radunović, v.f. dekana



MEDICINSKI FAKULTET

06.07.2023

Priloga	Broj	Prilog	Vrijednost
med	975		

UNIVERZITET CRNE GORE

Obrazac PD: Prijava teme doktorske disertacije

PRIJAVA TEME DOKTORSKE DISERTACIJE

OPŠTI PODACI O DOKTORANDU	
Titula, ime i prezime	Dr.med spec. Vuković Marko
Fakultet	Medicinski fakultet
Studijski program	Medicina
Broj indeksa	10/12
Ime i prezime roditelja	Milan Vuković
Datum i mjesto rođenja	09.05.1987, Podgorica
Adresa prebivališta	Bracana Bracanovica 88, 20000 Podgorica
Telefon	069 498 879
E-mail	Marko.vukovic09@gmail.com
BIOGRAFIJA I BIBLIOGRAFIJA	
Obrazovanje	<p>2022-2023: Subspecijalizacija (fellowship) iz oblasti Urološke onkologije na Medicinskom fakultetu, Univerziteta u Tübingenu, Njemačka (položio sa odličnom ocjenom).</p> <p>2015-2020: Specijalizacija iz oblasti Urologije, Medicinski fakultet Univerziteta u Beogradu, Srbija (položio sa odličnom ocjenom);</p> <p>2006-2012: Medicinski fakultet Univerziteta Crne Gore (diplomirao sa prosječnom ocjenom 9.68 (A)) ;</p> <p>2002-2006: Gimnazija: 'Slobodan Škerović', Podgorica (prosječna ocjena 4.93)</p> <p>1994-2002: Osnovna škola: "Milorad –Musa Burzan, Podgorica (prosječna ocjena 5.00)</p>
Radno iskustvo	<p>Od 2021: Urolog na Klinici za urologiju, KCCG, Podgorica;</p> <p>2015-2020: specijalizant na Klinici za urologiju KCCG;</p> <p>2012-2015: rad u HMP Podgorica, volonterski ran na Klinici za Neurohirurgiju KCCG, Podgorica</p>
Popis radova	<p>1. Vukovic M, Chamlati J.M, Hennenlotter J, et al. Prognostic impact of the Interleukin-1-Beta/Interleukin -1-Receptor –Antagonist axis in bladder cancer. Eur Urol. 2023; https://doi.org/10.1016/S0302-2838(23)01216-2</p>

2. Djordjevic D, Dragicevic S, **Vukovic M**. Mini-laparotomy radical cystectomy with limited bowel externalization during ileal conduit urinary diversion reduces the rate of postoperative complications: A matched-paired, single centered analysis. *Acta Chir Belg.* 2021; DOI:10.1080/00015458.2022.2025724.
3. Djordjevic D, Dragicevic S, **Vukovic M**. Technique selection of ureteroileal anastomosis in hautman ileal Neobladder with chimney modification: Reliability of patient-based selection strategy and its impact on ureteroenteric stricture rate. *Arch Ital Urol Androl.* 2021; 93:262-267
4. Djordjevic D, Dragicevic S, **Vukovic M**. Radical surgical treatment of a large seminal vesicle cyst causing acute urinary retention in a patient with Zinner syndrome: A case report and review of literature. *J Urol Surg.* 2021; 8: 291-293.
5. Cornford P, Smith EJ, MacLennan S... Pan-European National Urological Society IMAGINE Collaborative: **Vukovic M** et al. IMAGINE- impact assessment of guidelines implementation and education: the next frontier for harmonising urological practice across Europe by improving adherence to guidelines. *Eur Urol.* 2021; 79:173-76.
6. **Vukovic M**, Kavaric P, Vukmirovic F, Lekic S. 'Burned-out' primary testicular tumor: Is retroperitoneal lymph node biopsy mandatory prior to initiation of chemotherapy? Report of three cases and a review of th literature. *Andrologia.* 2021; doi:10.1111/and.14283.
7. Kavaric P, Rebronja A, Albijanic M, **Vukovic M**. Surgical technique of uretero-ileal anastomosis in patients with bilateral duplex ureters undergoing radical cystectomy and ileal conduit urinary diversion: Initial experience. *Acta Chir Belg.* 2021; 7:1-6.
8. Djordjevic D, **Vukovic M**. Functional results of Hautmann neobladder with chimney modification and Wallace ureteroileal anastomosis: initial experience with 22 patients. *Int Braz J Urol.* 2020; 47:426-435.
9. Kavaric P, Radovic N, Pratljacic D, Sabovic E, **Vukovic M**. Modified Wallace anastomotic technique reduces ureteroenteric stricture rates after ileal conduit urinary diversion. *Int Braz J Urol.* 2020; 46:446-455.
10. **Vukovic M**, Kavaric P, Magdelinic A, Nikomanis P, Tomovic S, Pelicic D. Perineural Invasion on biopsy specimen as predictor of tumor progression in aging male treated with radical prostatectomy. Could we use it for pre-surgical screening? *Aging Male.* 2019; doi: 10.1080/13685538.2019.1581758.
11. Kavaric P, Magdelinic A, **Vukovic M**. Running suture hemostatic technique versus standard reconstruction of the surgical bed in Zero - Ischemia time mini – flank Open partial nephrectomies. Retrospective, match-paired Case-control study. *Arch Ital Urol Androl.* 2019; doi: 10.481/aiua.2019.2.
12. Fatic N, Kuzmanovic I, Markovic D, Davidovic L, **Vukovic M**, Kostic D. Kidney injury secondary to endovascular treatment of renal artery stenosis. *Aniol Sosud Khir.* 2017; 23:159-163.
13. Pajovic B, Pajovic Lj, **Vukovic M**. Effectiveness of antibiotic treatment in infertile patients with sterile leukocytospermia induced by tobacco use. *Syst Biol Reprod Med.* 2017; doi: 10.1080/19396368.2017.1373158

14. Pajovic B, Dimitrovski A, Fatic N, Malidzan M, **Vukovic M**. Vacuum erection system in the treatment of organic erectile dysfunction and penile vascular differences between patients with DM typ I and DM typ II. *Aging Male* 2017;
 DOI:10.1080/13685538.2016.1230601.

15. Pajovic B, Radojevic N, Dimitrovski A, **Vukovic M**. Comparison of the efficiency of combined extracorporeal shock-wave therapy and triple therapy versus triple therapy itself Category III B chronic pelvic pain syndrome (CPPS). *Aging Male* 2016; DOI: 10.1080/13685538.2016.1197899.

16. Pajovic B, Dimitrovski A, Radojevic N, Tomovic S, **Vukovic M**. The Therapeutic Potential of Royal Jelly in Benign Prostatic Hyperplasia. Comparison with contemporary literature. *Aging Male* 2016; DOI: 10.3109/13685538.2016.1169400

17. Pajovic B, Radojevic N, Dimitrovski A, **Vukovic M**. A correlation between selenium and carnitine levels with Hypo - osmotic swelling test for sperm membrane in low - grade varicocele patients. *Eur Rev Med Pharmacol Sci*. 2016; 20: 598-604.

18. B. Pajovic, N. Radojevic, A. Dimitrovski, M. Radovic, R. Rolovic, **M. Vukovic**. Advantages of microsurgical varicocelectomy over conventional techniques. *Eur Rev Med Pharmacol Sci*. 2015; 19:532-538.

19. Pajovic B, Dimitrovski A, Radojevic N, **Vukovic M**. Comparison of Sperm Parameters in Patients with Infertility Induced by Genital Infection versus Varicocele. *Balkan Med J*. 2015; 32:255-259.

20. Pajovic B, Radojevic N, **Vukovic M**, Stjepcevic A. Semen analysis before and after antibiotic treatment of asymptomatic Chlamydia and Ureaplasma related pyospermia. *Andrologia* 2012; 44:18-28.

NASLOV PREDLOŽENE TEME

Na službenom jeziku	Biomarkeri kod karcinoma bešike: Kliničko-patološki i prognostički značaj ekspresije Ki-67
Na engleskom jeziku	Urinary biomarkers in bladder cancer: Clinicopathological and prognostic value of Ki-67 expression

Obrazloženje teme

Karcinom bešike jedan je od najčešće dijagnostifikovanih karcinoma u muškoj populaciji i taj se trend nastavlja kada se u obzir uzmu oba pola. U Europskoj uniji, starosna stopa incidencije je 20 kod muškaraca i 46 godina kod žena (1). Rizik od razvoja karcinoma bešike kod osoba <75 godina je između 2% i 4% za muškarce i 0,5% do 1% za žene.

Obzirom na veliki značaj navedene bolesti u morbiditetu opšte populacije, vrlo je važno unaprijediti dijagnostiku, prognostiku i terapiju karcinoma bešike, pri čemu bi uvođenje urinarnih biomarkera u standardni dijagnostički protokol pacijenata sa verifikovanim karcinomom bešike moglo dovesti do revolucionarnog napretka u tretmanu navedene bolesti. Ki-67 samo je jedan od brojnih biomarkera, čiji prognostički značaj kod karcinoma bešike još uvijek nije jasno

definisan. Naša studija ima za cilj da utvrdi njegov klinički, prediktivni potencijal kod osoba sa dijagnostikovanim karcinomom mokraćne bešike, te da utvrdi postojanje korelacije sa nekim drugim biomarkerima kod pacijenata sa invazivnim karcinomom bešike (IL-1 beta, IL1RA, AKT).

Pregled istraživanja

Uvod: Ki-67 je utvrđeni marker ćelijske proliferacije, a Ki-67 indeks korelira s kliničkim tokom nekoliko vrsta tumora, uključujući karcinom bešike. Međutim, kliničko-patološki i prognostički značaj Ki-67 kod karcinoma bešike ostaje nejasan. Shodno tome, cilj naše studije bio je procijeniti obrasce ekspresije i potencijalnu prognostičku i tumorsko-biološku ulogu Ki-67 kod pacijenata sa ne-mišićno invazivnim karcinomom bešike, a potom se osvrnuti na eventualnu korelaciju ovog biomarkera sa IL-1 β i IL-1RA kod invazivnog karcinoma, na osnovu naših prethodno objavljenih rezultata.

Materijali i metode: Studija bi uključivala dvije nezavisne grupe pacijenata skupine koje bi se sastojale od n=23 i 27 bolesnika (16x muškaraca, medijan dobi 65,5 godina, 23x <T1, <G2 i 20x muškaraca, 69 godine, 27x T1, \leq G2, medijana praćenja 44,5 mjeseci, respektivno) koji su bili podvrgnuti transuretralnoj resekciji tumora (TURB) između 02/96-12/06 i 06/03-12 /10. Uzorci tumora i benignog okolnog urotela (n=22) bili bi obrađeni imunohistokemijski i obojeni na Ki-67. Stepenski ekspresije Ki-67 bi bio izražen kao postotak broja imunološki obojenih jedara u ukupnom broju jedara tumorskih ćelija, bez obzira na intenzitet imunološkog bojenja. Ovo brojanje je sprovedeno u tri nasumično odabrana polja presjeka tkiva, pri uvećanju x400. Rezultat brojanja je bio u rasponu od 0-100%, a njegova granična vrijednost bila je 15%, gdje je „niska imunoreaktivnost“ definisana bojenjem jedra od < 15%, a „visoka“ za bojenje \geq 15%.

Očekivani rezultati: Očekujemo veću ekspresiju Ki-67 kod T1G2 stadijuma bolesti u odnosu na neinvazivne tumore (T2). Osim toga, ispitaćemo korelaciju između stepena ekspresije Ki-67 i progresije u T2 stadijum, kao i korelacije sa karcinom-specifičnim, progresivno-specifičnim i metastatski-specifičnim preživljavanjem pacijenata. Na kraju, osvrnućemo se na korelaciju sa biomarkerima IL-1beta i IL1RA, na osnovu eksterne analize naše prethodne studije.

Cilj i hipoteze

Cilj naše studije je procijenjena obrasca ekspresije i potencijalna prognostička uloga Ki-67 i ostalih biomarkera kod pacijenata sa karcinomom bešike. Hipoteza 1: ekspresija Ki-67 je veća kod pacijenata sa T1 karcinomom bešike; Hipoteza 2: veća ekspresija Ki-67 korelira sa kraćim vrremenom progresije tumora i metastatski-specifičnim preživljavanjem pacijenata; Hipoteza 3: Ki-67 pokazuje pozitivnu korelaciju sa ekspresijom IL-1beta u eksternoj analizi studije iz Tübingena.

Materijali, metode i plan istraživanja

Na osnovu institucionalne baze podataka identifikovani su bolesnici podvrgnuti proceduri TURB-a zbog neinvazivnog karcinoma bešike, u periodu od 2010 do 2020 godine, koji su dalje podijeljeni u dvije grupe. Iz uzorka tumorskog tkiva, stvoren je tkivni mikroniz (TMA), temeljen na identifikaciji reprezentativnih dijelova tumora i normalnog tkiva u bojenju hematoksilinom i eozinom. Nadalje, odgovarajući histopatološki benigni uzorci tkiva urotela iz okolnih područja obrađeni su na TMA i IHC obojeni na Ki-67. Prvu skupinu

činilo je 23 pacijenta, dok je u drugoj grupi bilo 27 ispitanika. Gradus i stadijum tumora procijenili su najmanje dva patologa s iskustvom u urogenitalnoj patologiji, na osnovu WHO 2016 TNM klasifikacijskom sustavu. Kliničko-patološke karakteristike upisane su u registar bolesnika..

TMA i imunohistokemijsko (IHC) bojenje

Da bi se dobile reprezentativna jedra za konstrukciju TMA, koristićemo paralelne sekcije obojene hematoksilinom i eozinom za identifikaciju reprezentativne pozicije jedra unutar uzoraka. IHC bojenje je sprovedeno prema protokolima proizvođača antitijela. Uzorci će biti inkubirani preko noći na 4 °C s ljudskim imunoglobulinima u razrjeđenjima 1:10 i 1:300, u razrjeđivaču pravih antitijela (DAKO, Glostrup, Danska). Nakon tri koraka ispiranja u Tris-puferiranoj fiziološkoj otopini, dodamo sekundarno Biozol HRP polimerno anti-kozje antitijelo (DAKO, Glostrup, Danska) sa 40 min inkubacije na sobnoj temperaturi. Nakon još tri koraka ispiranja, vizuelizacija će biti sprovedena sa Dako Liquid DAB-Substrat Chromogen System K3467 (DAKO, Glostrup, Danska) i kontrastnim bojenjem s hematoksilinom, kako je naveo proizvođač. Integrirana su dva ili više jedara svakog uzorka tumora i odgovarajućeg normalnog tkiva bešike. Odgovarajući histopatološki benigni uzorci tkiva dobijeni su iz parafinskih blokova bez tumora.

Imunohistokemijski protokol

Ki-67 skor izražen je kao procenat broja imunološki obojenih jedara među ukupnim brojem jedara tumorskih ćelija, bez obzira na intenzitet imunološkog bojenja. Ovo brojanje je izvedeno u tri nasumično odabrana polja presjeka tkiva karcinoma, pri povećanju x400. Ki-67 rezultat bio je u rasponu od 0-100%, a njegova granična vrijednost bila je 15%, gdje je „niska imunoreaktivnost“ definisana bojenjem jedra od < 15%, a „visoka“ za bojenje ≥ 15%. TMA je sproveden od strane dva nezavisna ispitivača, a divergentni rezultati su ponovno ocijenjeni. Mikroskopska analiza je izvedena na x100 i x400 povećanja.

Očekivani naučni doprinos

Uvođenje novih biomarkera u dijagnostici i prognostici invazivnih i neinvazivnih karcinoma mokraćne bešike.

Spisak objavljenih radova kandidata

Naveden u popisu radova

Popis literature

1. Wang JZ, Zhu W, Han J, Yang X, Zhou R, Lu HC, Yu H, Yuan WB, Li PC, Tao J, Lu Q, Wei JF, Yang H. The role of the HIF-1 α /ALYREF/PKM2 axis in glycolysis and tumorigenesis of bladder cancer. *Cancer Commun (Lond)*. 2021; 41:560-575.
2. Huang W, Li Y, Zhang C, Zha H, Zhou X, Fu B, Guo J, Wang G. IGF2BP3 facilitates cell proliferation and tumorigenesis via modulation of JAK/STAT signalling pathway in human bladder cancer. *J Cell Mol Med*. 2020; 24:13949-13960.
3. Massari F, Ciccarese C, Santoni M, Iacovelli R, Mazzucchelli R, Piva F, Scarpelli M, Berardi R, Tortora G, Lopez-Beltran A, Cheng L, Montironi R. Metabolic phenotype of bladder cancer. *Cancer Treat Rev*. 2016; 45:46-57.

4. Rausch S, Hennenlotter J, Teepe K, Kuehs U, Aufderklamm S, Bier S, Mischinger J, Gakis G, Stenzl A, Schwentner C, Todenhöfer T. Muscle-invasive bladder cancer is characterized by overexpression of thymidine kinase 1. *Urol Oncol*. 2015; 33:426.e21-9.
5. Xia H, Green DR, Zou W. Autophagy in tumour immunity and therapy. *Nat Rev Cancer*. 2021; 21:281-297.
6. Deretic V. Autophagy in inflammation, infection, and immunometabolism. *Immunity*. 2021. 9; 54:437-453.
7. Vetterlein MW, Roschinski J, Gild P, Marks P, Soave A, Doh O, Isbarn H, Höppner W, Wagner W, Shariat SF, Brausi M, Büscheck F, Sauter G, Fisch M, Rink M. Impact of the Ki-67 labeling index and p53 expression status on disease-free survival in pT1 urothelial carcinoma of the bladder. *Transl Androl Urol*. 2017; 6:1018-1026.
8. Tian Y, Ma Z, Chen Z, Li M, Wu Z, Hong M. Clinicopathological and prognostic value of Ki-67 expression in bladder cancer: a systematic review and meta-analysis. *PLoS One* 2016; 11:e0158891.
9. Liu C, Xu P, Chen D, Fan X, Xu Y, Li M, Yang X, Wang C. Roles of autophagy-related genes Beclin-1 and LC3 in the development and progression of prostate cancer and benign prostatic hyperplasia. *Biomed Rep*. 2013; 1:855-860.
10. Liu GH, Zhong Q, Ye YL, Wang HB, Hu LJ, Qin ZK, Zeng MS, Zeng BH. Expression of beclin 1 in bladder cancer and its clinical significance. *Int J Biol Markers*. 2013; 28:56-62.
11. Hyera Kim, Su Jin Lee, In Kyoung Lee, Suejean C Min, Hyun Hwan Sung, Byong Chang Jeong, Jeeyun Lee, Se Hoon Park. Synergistic Effects of Combination Therapy with AKT and mTOR Inhibitors on Bladder Cancer Cells. *Int J Mol Sci* . 2020; 21:2825.
12. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. *Nature*. 2008; 454:436-44.
13. Chen N, Debnath J. Autophagy and tumorigenesis. *FEBS Lett*. 2010; 584:1427-35.
14. Matsumoto H, Munemori M, Shimizu K, Fujii N, Kobayashi K, Inoue R, Yamamoto Y, Nagao K, Matsuyama H. Risk stratification using Bmi-1 and Snail expression is a useful prognostic tool for patients with upper tract urothelial carcinoma. *Int J Urol*. 2016; 23:1030-1037.
15. Wang F, et al. IL-1 β receptor antagonist (IL-1Ra) combined with autophagy inducer (TAT-Beclin1) is an effective alternative for attenuating extracellular matrix degradation in rat and human osteoarthritis chondrocytes. *Arthritis Res Ther*. 2019. PMID: 3129198
16. de Luca A, Smeekens SP, Casagrande A, Iannitti R, Conway KL, Gresnigt MS, et al. IL-1 receptor blockade restores autophagy and reduces inflammation in chronic granulomatous disease in mice and in humans. *Proc Natl Acad Sci*. 2014; 111:3526–3531.
17. Crişan TO, et al. Inflammasome-independent modulation of cytokine response by autophagy in human cells. *PLoS ONE*. 2011; 6:e18666.
18. Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours. *Eur Urol*. 2016; 70:106-119.
19. Chen Y, Yang Z, Deng B, Wu D, Quan Y, Min Z. Interleukin 1 β /1RA axis in colorectal cancer regulates tumor invasion, proliferation and apoptosis via autophagy. *Oncol Rep*. 2020; 43:908-918.

20. John A, Günes C, Bolenz C, Vidal-Y-Sy S, Bauer AT, Schneider SW, Gorzelanny C. Bladder cancer-deriv interleukin-1 converts the vascular endothelium into a pro-inflammatory and pro-coagulatory surface. *BN Cancer*. 2020; 20:1178.

SAGLASNOST PREDLOŽENOG/IH MENTORA I DOKTORANDA SA PRIJAVOM

Odgovorno potvrđujem da sam saglasan sa temom koja se prijavljuje.

Prvi mentor Miodrag Aćimović

Drugi mentor (Ime i prezime)

Doktorand Marko Vuković

(Potpis)

IZJAVA

Odgovorno izjavljujem da doktorsku disertaciju sa istom temom nisam prijavio/la ni na jednom drugom fakultetu.

U Podgorici,
07.06.2023

Marko Vukovic

Ime i prezime doktoran

Na osnovu Odluke Vijeća Medicinskog fakulteta o formiranju Komisije za doktorske studije, broj: 392/7 od 21.02.2019. godine a u skladu sa tačkom 3.5 Vodiča za doktorske studije UCG-Centar za doktorske studije, nakon razmatranja ispunjavanja uslova za prijavu teme doktorske disertacije i poštujući princip kopetentnosti, Komisija za doktorske studije dostavlja Vijeću Medicinskog fakulteta

INICIJALNI PRIJEDLOG
sastava Komisije za ocjenu prijave doktorske disertacije

1. Kandidat: **dr med Marko Vuković**

2. Tema istraživanja: «Biomarkeri kod karcinoma beške: Kliničko-patološki i prognostički značaj ekspresije Ki-67»


3. Komisija za ocjenu prijave doktorske disertacije:

- **Prof. dr Filip Vukmirović**, redovni profesor Medicinskog fakulteta Univerziteta Crne Gore, predsjednik
- **Prof. dr Miodrag Aćimović**, redovni profesor Medicinskog fakulteta Univerziteta u Beogradu - mentor
- **Prof. dr Vladimir Todorović**, redovni profesor Medicinskog fakulteta Univerziteta Crne Gore, član

MEDICINSKI FAKULTET
Komisija za doktorske studije

Prof. dr Filip Vukmirović





Univerzitet Crne Gore
Adresa / Address: Cetinjska br. 2
81000 Podgorica, Crna Gora
Telefon / phone: 00382 20 414 255
fax: 00382 20 114 230
mail: rektorat@ucg.me
web: www.ucg.ac.me
University of Montenegro

Broj / Ref: 03 - 1336

Datum / Date: 19. 04. 2019

Na osnovu člana 72 stav 2 Zakona o visokom obrazovanju („Službeni list Crne Gore“ br. 44/14, 47/15, 40/16, 42/17, 71/17 55/18 i 3/19) i člana 32 stav 1 tačka 9 Statuta Univerziteta Crne Gore, Senat Univerziteta Crne Gore, na sjednici održanoj 19. aprila 2019. godine, donio je

ODLUKU O IZBORU U ZVANJE

Dr **FILIP VUKMIROVIĆ** bira se u akademsko zvanje redovni profesor Univerziteta Crne Gore za oblast Patologija iz Dijagnostičke grupe bazičnih medicinskih predmeta (Patološka anatomija, osnovne studije, studijski program Medicina, Opšta patologija, osnovne studije, studijski program Stomatologija i Oralna patologija, osnovne studije, studijski program Stomatologija) na Medicinskom fakultetu Univerziteta Crne Gore, na neodređeno vrijeme.

~~SENAT UNIVERZITETA CRNE GORE
PREDSJEDNIK~~

~~Prof. dr Danilo Nikolić, rektor~~

BIOGRAFIJA

Dr Vukmirović je diplomirao na Medicinskom fakultetu Univerziteta u Prištini 1992. godine.

Od 2000. godine, pored rada sa pacijentima, dr Vukmirović je angažovan u nastavi na studijskim programima medicine i stomatologije na Medicinskom fakultetu u Podgorici.

Zvanje specijaliste patološke anatomije je stekao 2003. godine, na Medicinskom fakultetu Univerziteta u Novom Sadu, od kada radi na Odjeljenju patologije Kliničkog centra Crne Gore.

Doktorske studije je završio na Medicinskom fakultetu u Foči, Univerziteta u Istočnom Sarajevu, Republika Srpska, Bosna i Hercegovina 2007. godine. U fokusu njegovog istraživanja bila je procjena kliničkog značaja vaskularnog i epidermalnog faktora rasta kod karcinoma dojke i želuca.

Od 2009. do 2011. godine predsjedavao je Etičkim komitetom Kliničkog centra Crne Gore.

Titulu vanrednog profesora na Univerzitetu Crne Gore, na katedri za Patološku anatomiju, dobio je 2013. godine.

Od 2017. godine obavlja funkciju direktora Centra za nauku u Kliničkom centru Crne Gore.

Direktor je Centra za patologiju i specijalista patološke anatomije.

Autor je i koautor većeg broja naučnih radova.

2020	SCI, SCIE, SSCI, A&HCI	Nikoleta Sjekloća, Snjezana Tomić, Ivana Mrklic, Filip Vukmirović, Ljiljana Vučković, Ingrid Belas Lovasić, Marina Maras-Simunić	Prognostic value of IMP3 immunohistochemical expression in triple negative breast cancer	Medicine
2019	SCI, SCIE, SSCI, A&HCI	Restović I, Bočina I, Vukojević K, Kero D, Filipović N, Raonić J, Vučinić J, Vukmirović F, Vučković Ij, Saraga Babić M.	Time course and expression pattern of the neuronal markers in the developing human spinal cord	Int J Dev Neurosci
2017	SCI, SCIE, SSCI, A&HCI	Vukmirović Mihailo, Bošković Aneta, Bukumirić Zoran, Tomašević-Vukmirović Irena, Vukmirović Filip	Predictors and outcomes of new- onset atrial fibrillation in patients with acute myocardial infarction	Vojnosanitetski pregled
2017	SCI, SCIE, SSCI, A&HCI	Vukmirović M, Bošković A, Tomašević Vukmirović I, Vujadinović R, Falić N, Bukumirić Z, Vukmirović F	Predictions and Outcomes of Atrial Fibrillation in the Patients with Acute Myocardial Infarction	Open medicine
2015	SCI, SCIE, SSCI, A&HCI	Milošević V., Vukmirović Filip, Zindović M., Krstić M., Milenković S., Jančić S.	Interplay between expression of leptin receptors and mucin histochemical aberrations in colorectal adenocarcinoma	Romanian journal of morphology and embryology
2015	SCI, SCIE, SSCI, A&HCI	Milošević V., Vukmirović Filip, Krstić M., Zindović M., Stojanović D., Jančić S.	Involvement of leptin receptors expression in proliferation and neovascularization in colorectal carcinoma	Journal of BUON
2014	SCI, SCIE, SSCI, A&HCI	Vukmirović, F., Vukmirović, M. & Tomašević-Vukmirović, I.	Papillary fibroelastoma of the aortic valve	Vojnosanitetski pregled
2013	SCI, SCIE, SSCI, A&HCI	Vukmirović, F., Zejnilović, N., Ivović, J.	Liposarcoma of the Paratesticular Tissue and Spermatic Cord	Vojnosanitetski pregled
2013	SCI, SCIE, SSCI, A&HCI	Vukmirović, M., Angelkov, A., Vukmirović, F., Tomašević Vukmirović, I.	Successful Implantation of a Biventricular Pacing and Defibrillator Device via a Persistent Left Superior Vena Cava	Vojnosanitetski pregled
2013	SCI, SCIE, SSCI	Radojević, N., Vukmirović, F., Čurović, I. & Šoć, M.	Asymptomatic Syphilitic Massive Necrosis of the Spleen in Late Syphilis	International Journal of STD & AIDS

	A&HCI			
2013	SCI, SCIE, SSCI, A&HCI	Vukmirović, F., Tomašević Vukmirović, I. & Vukmirović, M.	<u>Clinicopathological Features of Ovarian Brenner Tumors in Montenegro</u>	Central European Journal of Medicine
2013	SCI, SCIE, SSCI, A&HCI	Vukmirović, F., Vukmirović, M., Tomašević Vukmirović, I., Kavarić, P.	<u>Renal Lipoma</u>	Central European Journal of Medicine
2013	SCI, SCIE, SSCI, A&HCI	Vukmirović, F., Tomašević Vukmirović, I. & Vukmirović, M.	<u>Von Meyenburg complex (hamartoma of the bile duct) mimicking liver metastases</u>	Vojnosanitetski pregled
2012	SCI, SCIE, SSCI, A&HCI	Vujisić, S., Radulović, Lj., Knežević-Apostolski, S., Petković, S., Vukmirović, F., Apostolski, S.	<u>Disulfiramska polineuropatija</u>	Vojnosanitetski pregled



УНИВЕРЗИТЕТ У БЕОГРАДУ

Адрес: Универзитетски трг 1, 11000 Београд, Република Србија
Тел: 011 260400, Факс: 011 260401, Е-пошта: zabavcar@unibg.ac.rs

Београд, 12. маја 2021. године
62 Број: 62/2021-661/3-11
ДК

На основу чл. 74. Закона о високом образовању („Службени гласник РС”, бр. 88/17, 93/18 и 6/19), чл. 43. и 44. Закона о Универзитету у Београду („Службени гласник Универзитета у Београду”, бр. 201/19, 202/19, 213/20, 214/20 и 217/20), чл. 26. ст. 1 и ст. 2 тач. 1 Правилника о начину и поступку стицања звања и заснивања радних односа наставника Универзитета у Београду („Службени гласник Универзитета у Београду”, бр. 203/17 и 210/19) и Правилника о организационим условима и статусним звањима наставника на Универзитету у Београду („Службени гласник Универзитета у Београду”, бр. 192/16, 185/16, 197/17, 199/17 и 207/18) а на предлог Изборног већа Медицинског факултета, бр. 797/12 од 4. фебруара 2021. године и изабраног Већа научне области медицинских наука, 02/01 бр. 4/2020-891/2-21 од 20. априла 2021. године, Савета Универзитета, на седници одржаној 12. маја 2021. године, одлучено је:

ОДЛУКУ

ИРА СЕ др **Милорад Алексић**, у звање редовног професора на Универзитету у Београду – Медицински факултет, за ужу научну област Хирургија са анестезиолошком специјализацијом.

ОБРАЗЛОЖЊЕ

Медицински факултет (у даљем тексту Факултет) је 7. октобра 2020. године, у публикацији „Писмо”, објавио конкурс за избор у звање редовног професора, за ужу научну област Хирургија са анестезиолошком специјализацијом, на основу конкурса Факултета.

Реферат Комисије за припрему реферата о припадном кандидатном списку је на увид јавности дана 9. новембра 2020. године, на сајту и одласног Већа Факултета.

На основу предлога Комисије за припрему реферата о припадном кандидатном списку, Изборно веће Факултета, на седници одржаној 4. фебруара 2021. године, донело је одлуку о утврђивању предлога да се кандидат др **Милорад Алексић** изабере у звање редовног професора.

Факултет је 17. фебруара 2021. године доставио Универзитету кандидатни списак за избор у звање на прописаним основањима.

Универзитет је министарству димензионарну копију је доставио Факултетом достављеном на веб-страници Универзитета 13. априла 2021. године.

Високо поштом, у складu са прописима, издати на основу одлуке 19. септембра 2021. године, Сабора Републике Српске, Министарство просвете, науке и спорта, и на основу одлуке Републичког завода за издаваштво.

Универзитет у Сарајеву, на основу одлуке 17. маја 2021. године, у складу са одредбама Закона о универзитетима у Сарајеву, од 14. и 15. маја 2016. године и одлуком Републичког завода за издаваштво, као и на основу одлуке Републичког завода за издаваштво, одлуке о издавању наставних наставника на Универзитету у Сарајеву, на основу одлуке о издавању.

ГРОБА ОПРАВОМ ДЈУ:

Против ове одлуке издатије пријављено жалбу, и пријави жалбу, Сабора Универзитета, преко Факултета. Жалба се заснива на одлуку о издавању 5 дана од дана издавања одлуке.

**ПРЕДСЕДНИЦА СЕНАТА
РЕКТОРКА**

[Својеручни потпис]
проф. др. Милана Поповић

CURRICULUM VITE

Miodrag Z Acimovic, MD, PhD

Education

Medical School:

1986-1992, Belgrade University, School of Medicine

Residency:

1992-1994 Interventional Radiology, Institute of Radiology, Clinical Center of Serbia, Belgrade, Serbia

Urology: 1994-1999, Medical School, Belgrade University, university Urological clinic
January 1999. - Board Certified Specialist in Urology

Master of Medical Sciences in Urology:

March 1998. - Master's Theses Defended; Title: "The role of Prostatic Specific Antigen (PSA) in the early detection and monitoring of prostate cancer"

PhD:

2004 - 2007, Medical School, Belgrade University

PhD Theses: "Correlation of expression of mitotic cyclins, high molecular weight cytokeratin and clinical parameters in the evaluation of prostate cancer aggression".

Dr. Acimovic has learned oncological and reconstructive urology from Prof. Hadzi-Djokic Jovan (orthotopic and continental urinary reservoirs) and urogenital reconstruction from Prof. Perovic Sava (penile and urethral surgery). In addition to open surgery, he is also involved in laparoscopic surgery and laser surgery, and he is one of the pioneers of laparoscopy oncological and reconstructive surgery in Serbia and the region.

Employment

1st Urology Department (Head of Department 2013- present) Clinic of Urology, Clinical Center of Serbia, Resavska 51, 11000 Belgrade, Serbia, 1994-present.

Academic positions

Professor of Surgery, Medical School, University of Belgrade

Member of the Program council in front of urology for doctoral studies in reconstructive surgery at the Faculty of Medicine, University of Belgrade

Awards

1. First prize for best poster presentation in the session: Urethral Strictures and urethroplasty, 27th EAU (European Association of Urology) Congress, Paris 2012: „Single stage repair of obliterated anterior urethral strictures by combined buccal mucosa graft and longitudinal dorsal penile skin flap“, Kojovic V, Acimovic M, Tulic C, Djordjevic M
2. First prize for best poster presentation VII th South East Congress of Urology, Sarajevo, 2007., Acimovic M, Hadzi Djokic J, Tulic C: „Prognosis of biochemical relaps after radical prostatectomy based on multivariant analysis“. EUR UROL 2007;2(5):p 77.
3. First prize for best paper: 1st South East Congress of Urology 2005. Acimovic M, Tulic C „Standardization of transrectal ultrasound guided biopsy“.
4. First prize for best poster presentation: „Increased number of detected Carcinoma of Prostate in group of patients with PSA value 4-10ng/ml by 10-12 core biopsy technic“, Durutovic O, Acimovic M ESU (European school of Urology) Belgrade 2001.
5. Winner of the The City of Belgrade Annual Award in the field of medicine, for 2015.

Memberships in International Societies

EAU– European Association of Urology,

ESGURS – European Society for Genitourinary Reconstructive Surgeons,

Memberships in National Societies

SUA -Serbian Urological Association, vice president (2013.-2016.)

SUS-Serbian Urological Section, vice president (2014.-present)

MUA-Macedonian Urological Association honorary member (2016.)

BAU Balearic Association of Urology, vice president

Member of the Republic Expert Commission of Serbia for Urology and Nephrology (representing Urology). (2012.-present).

Journal's Editorial Board

1. International Editorial Board: Hellenic Urology. Publisher Home Huanet

Reviewer in Journals and Books

1. World Journal of Urology
2. International Urology and Nephrology

Invited Lectures

- 35th Athenian Urology days Invited speaker “Urethroplasty for pan urethral disease”, chairman Urogenital reconstruction session, Athens, Greece, 2016.
- SANU (Serbian Academy of Science and Art): The picture speaks more than a thousand words: invited speaker: “Surgery of Morbus Peyronie’s associated with ventral penile curvature (grafting procedure based on geometrical principle)”, International Symposium, Nis, Serbia 2018.

- 3rd Surgical Workshop Sava Perovic of complex UroGenital Reconstructive Surgery in Adult, invited speaker: Anterior Urethroplasty, Belgrade, Serbia, 2010.
- Serbian-Italian Urological Days, Live Surgical Workshop, SANU (Serbian Academy of Science and Art): "Laparoscopic radical prostatectomy", invited speaker, chairman Belgrade, December 2015.
- Urethral Reconstruction, Semi-Live Surgical Workshop, SANU (Serbian Academy of Science and Art): Invited speaker, chairman, "Pan-Urethral Strictures One-stage repair" Belgrade December 2016.
- 1st National Congress of The Urological Section of Serbian Medical Association and Regional Joint Meeting and ESU course "Update on treatment of Peyronie's disease"; Pro et Contra: "Bipolar TUR vs Greenlight laser for BPH" September, 28-30th, 2017, Belgrade, Serbia
- Croatian Urological Association Congress International Symposium invited speaker "Surgical Treatment of Peyronie's Disease", Porec, October 2017.
- 11th Osijek urological days, International Symposium invited speaker "Bulbar urethral stricture" and "Interstitial Brachytherapy in the Treatment of Prostate Carcinoma", Osijek, Croatia 2015.
- Urology today, International Symposium, invited speaker "Radical Prostatectomy versus Brachytherapy in the treatment of prostate carcinoma" Olympia Hotel Vodice, 2018.
- Urology News, International Symposium, invited speaker "New trends in Prostate Cancer Treatment", MANU (Macedonian Academy of Science and Art), Skopje, Macedonia, 2016
- XIV International Symposium of Pediatric and Urology "Surgical treatment of pan-urethral stricture" Mostar, 2017.
- Balkan Congress of Urology, invited speaker "Complex urethral strictures" Metropol Hotel Ohrid, North Macedonia 2019.
- MIPS (Mediterranean Incontinence and Pelvic Floor Society) Educational Course, Invited speaker: "Female Orthotopic Neobladder", Sarajevo, 9-10 April, 2016.
- Croatian Urological Association Congress and International Symposium; invited speaker "Surgical treatment of penile curvature" and "Pan urethral disease", Split, 2015.
- 3rd Congress Macedonian Urological Association and International Symposium invited speaker: "Treatment of urinary incontinence after radical prostatectomy" MANU (Macedonian Academy of Science and Art), Skopje, Macedonia, 2018.

- IAAS (International Association for Ambulatory Surgery) Training Workshop on Ambulatory Surgery, invited speaker: "One Day Surgery in Urology", December 2013., Belgrade.

Educational visits

Mansoura Urology and Nephrology, Cours Invasive Bladder Cancer and Urinary Derivation, Mansoura, 2 weeks, Egypt, October 2009.

Argus training course Munich, Germany, November 2014

Laparoscopic Surgery of prostate, two months visit, September, October 2011., Slovenj Gradec, Slovenia.

Using the High Power Diodlaser in Urology, Urology clinic Szeged, October 2011.

Laparoscopic and Robotic Surgery, Advanced Cours Roma, Italy Jun 2012.

Thulium Laser Surgery of Prostate, short visit, Beckum Germany, July 2017.

Reconstructive Urogenital Surgery, short visit, Essen germany, 2018.

ESU Masterclass for practicing urologists on medical tumor treatment, Barcelona, Spain, 29 September – 1 October 2006.

Visits and demonstration surgeries from 20012-2018:

Croatia (Split); Bosnia and Herzegovina (Mostar, Banja Luka), North Macedonia (Skopje).

Organizing courses

- Serbian-Italian Urological Days, Live Surgical Workshop, SANU (Serbian Academy of Science and Art): Belgrade, December 2015. President
- Urethral Reconstruction, Semi-Live Surgical Workshop, SANU (Serbian Academy of Science and Art): Belgrade December 2016. President
- XXII Serbian Urological Congress and Regional Join Meeting and EAU—ESU Course, Belgrade 17-18. April 2015. Vice President
- 1st National Congress of the Urological Section of Serbian Medical Association and Regional Join Meeting, Belgrade, September, 2017. Vice President
- Organizing Committee School of Urological Surgery, Live Surgery: Urethra, Penis, Stress Urinary Incontinence 2014, Pirot, Serbia
- Organizing Committee School of Urological Surgery, Live Surgery: Prostate 2016, Pirot, Serbia
- Organizing Committee Symposium Urological Endoscopy and Laparoscopy, Nis, 2014.
- Organizing Committee New Trends in the Diagnosis and Treatment of Prostate Cancer, Nis, Serbia, 2016
- Organizing Committee Balkan Congress of Urology, Metropol Hotel Ohrid, North Macedonia 2019.

Original articles JCR and MEDLINE

1. Acimovic M, Zivkovic M, Georgescu AV, Matei IR, Bumbasirevic Repair of urethral injury associated with penile fracture using buccal mucosa graft: A novel therapeutic approach for complex cases. *U. Injury*. 2020 Dec;51 Suppl 4:S114-S116. doi: 10.1016/j.injury.2020.02.116. Epub 2020 Feb 24. PMID: 32115211
2. Rajković KM, Dabić-Stanković K, Stanković J, Aćimović M, Đukanović N, Nikolin B. Modelling and optimisation of treatment parameters in high-dose-rate mono brachytherapy for localised prostate carcinoma using a multilayer artificial neural network and a genetic algorithm: Pilot study. *Comput Biol Med*. 2020 Nov;126:104045. doi: 10.1016/j.combiomed.2020.104045. Epub 2020 Oct 13. PMID: 33099047
3. Petrovic J, Acimovic M, Jovicevic A, Rafailovic D, Petrovic I, Dzamic Z, Pejic T, Hadzi-Djokic The assessment of knowledge and attitudes of men in Serbia about prostate cancer and possibilities for its early detection and treatment in 2011: a cross-sectional study. *J. J BUON*. 2019 Jan-Feb;24(1):233-238. PMID: 30941975

4. Acimovic M, Milojevic B, Milosavljevic M, Skrodzka M, Radovanovic M, Rafailovic D, Dzamic Z, Djokic JH, Djinovic R. Primary dorsal buccal mucosa graft urethroplasty for anterior urethral strictures in patients with lichen sclerosus. *Int Urol Nephrol*. 2016; Apr;48(4):541-5.
5. Hadzi-Djokic J, Pejcic TP, Acimovic M. Vesico-vaginal fistula: report of 220 cases. *Int Urol Nephrol*. 2009;41(2):299-302.
6. Djordjevic ML, Bizic M, Stanojevic D, Bumbasirevic M, Kojovic V, Majstorovic M, Acimovic M, Pandey S, Perovic SV. Urethral Lengthening in metoidioplasty (female-to-male sex reassignment surgery) by combined buccal mucosa graft and labia minora flap. *Urology*. 2009;74(2):349-53.
7. Hadzi-Djokic J, Pejcic T, Stamenkovic V, Petrovic M, Acimovic M: Buccal mucosal graft interposition in the treatment of recurrent vesicovaginal fistula: A report on two cases. *Taiwan J Obstet Gynecol*. 2015 Dec;54(6):773-5.
8. Acimovic M, Tulic C, Dzamic Z, Pejcic T, Ladjevic N, Jovanovic M, Janicic A, Radosavljevic R, Hadzi-Djokic J: Results of application of orthotopic urine diversion according to Studer. *Acta Chir Iugosl*. 2007;54(4):29-32.
9. Hadzi-Djokic J, Basic D, Dzamic Z, Acimović M: Retrocaval ureter based on a series of 16 cases. *Prog Urol*. 2009;19(1):33-8.
6. Pejčić T, Loncar Z, Rafailović D, Acimović M, Dzamić Z, Hadzi-Djokić J. Genitourinary injuries associated with pelvic fractures. *Acta Chir Iugosl*. 2013;60(2):117-20.
7. Jovanović M, Džamić Z, Acimović M: Trans-Obturator-Tape (T.O.T.) "outside-in" approach in surgical treatment of female stress urinary incontinence. *Acta Chir Iugosl*. 2014;61(1):69-72.
8. Milutinovic D, Dzamic Z, Acimovic M: Evaluation and management of traumatic rupture of the corpora cavernosa. *Acta Chir Iugosl*. 2007;54(2):131-4.
9. Jovanovic M, Soldatovic I, Janjic A, Vuksanovic A, Dzamic Z, Acimovic M, Hadzi-Djokic J. Diagnostic value of the nuclear matrix protein 22 test and urine cytology in upper tract urothelial tumors. *Urol Int*. 2011;87(2):134-7.

10. Acimovic M, Dabic-Stankovic K, Pejcić T, Dzamic Z, Rafailovic D, Hadzi-Djokić J. Preoperative Gleason score, percent of positive prostate biopsies and PSA in predicting biochemical recurrence after radical prostatectomy. *J BUON*. 2013;18(4):954-60.
11. Pejčić T, Acimović M, Dzamić Z, Maksimović H, Marković B, Hadzi-Djokić J. Bilateral triple renal pelvis: a case report. *Vojnosanit Pregl*. 2015 Feb;72(2):185-7.
12. Pejčić T, Acimović M, Dzamić Z, Radovanović M, Hadzi-Djokić J. Benign prostatic hyperplasia and prostate-specific antigen. *Vojnosanit Pregl*. 2015 May;72(5):447-53. Review.
13. Hadzi-Djokić J, Pejčić T, Bašić D, Vukomanović I, Dzamić Z, Acimović M. Idiopathic retroperitoneal fibrosis: A Report on 15 Patients. *Vojnosanit Pregl*. 2015 Oct;72(10):928-31.
14. Janićić A, Bumbasirević U, Pekomezović T, Cekerevac M, Acimović M, Dzamić Z, Tulić C. Partial versus radical nephrectomy for pT1a renal cancer in Serbia. *J BUON*. 2016 Nov-Dec;21(6):1449-1453.
15. Petrović J, Acimović M, Jovicević A, Rafailović D, Petrović I, Dzamić Z, Pejcić T, Hadzi-Djokić J. The assessment of knowledge and attitudes of men in Serbia about prostate cancer and possibilities for its early detection and treatment in 2011: a cross-sectional study. *J BUON*. 2019 Jan-Feb;24(1):233-238.
16. Gojnić M, Dugalić V, Branković M, Stojanović I, Acimović M, Vasiljević B. Is insulin-dependent diabetes and obesity a predisposition for endometrial and pancreatic carcinoma? *Clin Exp Obstet Gynecol*. 2010;37(2):152-4.
17. Lazić M, Hadzi-Djokić J, Bašić D, Acimović M. Congenital arteriovenous fistula of the horseshoe kidney with multiple hemangiomas. *Srp Arh Celok Lek*. 2012;140(7-8):508-10.
18. Dzamić Z, Hadzi-Djokić J, Tulić C, Vuksanović A, Lalić N, Acimović M, Janićić A, O. Durutović. Quality of life in patients with a modified Mainz-pouch II urinary diversion. *Acta Chir Jugosl* 1999;46(1): 11-13.
19. Acimović M, Tulić C, Dzamić Z, Radosavljević R, Filimonović J, Jovanović M, Mitrović D, Govedarević V, Hadzi-Djokić J. Standardization of transrectal ultrasound guided biopsy. *Acta Chir Jugosl*. 2005;52(4):41-4.

20. Acimovic M, Govedarevic V, Mitrovic D, Radosavljevic R, Hadzi-Djokic J, Tulic C, Dzamic Z, Jovanovic M, Zivkovic K, Babic M, Markovic-Lipkovski J: Correlation of high-molecular cytokeratin in tissue of prostate cancer with Gleason score and PSA. *Acta Chir Jugosl.* 2005;52(4):45-50.
21. Acimovic M, Dzamic Z, Tulic C, Lalic N, Janicic A, Radosavljevic R, Mitrovic D, Hadzi-Djokic J: The possibilities of age reference values of PSA density in prostatic cancer screening. *Acta Chir Jugosl.* 2005;52(4):77-80.
22. Hadzi-Djokic J, Acimovic M, Dzamic Z, Jovanovic M, Basic D, Colovic V, Petrovic M, Obradovic G: Radical retropubic prostatectomy – results in 127 surgically treated patients. *Acta Chir Jugosl.* 2005;52(4):55-8.
23. Džamić Z, Radovanović M, Aćimović M: Surgical care vesicovaginal fistulas in women with malignant gynecological disease. *Acta Chir Jugosl.* 2014;61(1):25-7.
24. Radosavljevic R, Hadzi-Djokic J, Acimovic M, Tulic C, Dzamic Z, Djokic M, Micic S: Histopathological evaluation of radical prostatectomy in the treatment of localized prostate cancer. *Acta Chir Jugosl.* 2005;52(4):109-12.
25. Stojanovic S, Radosevic-Jelic Lj, Tulic C, Popov I, Babic D, Acimovic M, Masulovic D: Radical radiotherapy for localized prostate cancer in elderly. *Acta Chir Jugosl.* 2005;52(4):103-8.
26. Aćimović M, Rafailović D, Bumbaširević U, Babić U, Šantrić V, Stanić M, Džamić Z, Hadži-Djokić J: Diode laser vaporization of prostate as treatment for benign prostatic enlargement: initial results of 73 patients with 1 year follow-up. *Acta Chir Jugosl.* 2014;61(1):21-4.
27. Filimonovic J, Gvozdic B, Krivic B, Acimovic M, Tulic C, Hadzi-Djokic J: Anesthesia for radical prostatectomy. *Acta Chir Jugosl.* 2005;52(4):113-7.
28. Pejcic T, Hadzi-Djokic J, Acimovic M, Topuzovic C, Milkovic B, Janjic A: Urinary prostate specific antigen: is the clinical use likely? *Acta Chir Jugosl.* 2005;52(4):69-74.

29. Hadzi-Djokic J, Lalic N, Dzamic Z, Acimovic M, Tulic C, Markovic Z: Determination of biochemical relapse after radical prostatectomy by biological detection limit (BDL) after cystoprostatectomy using two PSA assays. *Acta Chir Jugosl.* 2005;52(4):59-61.
30. Dzamic Z, Acimovic M, Tulic C, Basic D, Milutinovic D, Hadzi-Djokic J: Treatment of emergency surgical complications of kidney transplantations. *Acta Chir Jugosl.* 2007;54(2):91-4.
31. Ladjevic N, Likic-Ladjevic I, Krivic B, Filimonovic J, Acimovic M, Dragicevic D, Argirovic R : Comparasion of Granisetron and Metoclopramide for prevention of nausea and vomiting following total cystectomy and ileal conduit. *Acta Chir Jugosl.* 2007;54(2):19-22.
32. Jovanovic M, Hadzi-Djokic J, Dzamic Z, Acimovic M: Evaluation of the BARD BTA test in the diagnosis of upper urinary tract tumors. *Acta Chir Jugosl.* 2007;54(4):19-24.
33. Dzamic Z, Hadzi-Djokic J, Acimovic M, Jovanovic M, Filimonovic J, Tulic C, Ladjevic N, Milkovic B, Pejic T: Modified Mainz pouch II urinary diversion and quality of life. *Acta Chir Jugosl.* 2007;54(4):57-62.
34. Pejic T, Hadzi Djokic J, Acimovic M, Markovic B, Maksimovic H Milkovic B, Kajmakovic B: Local recurrence of bladder cancer after cystectomy with orthotopic bladder substitution and ileal conduit. *Acta Chir Jugosl.* 2007;54(4):63-68.
35. Obradovic G, Stanojevic D, Jakovljevic J, Hadzi-Djokic J, Acimovic M: Five-year experience with urinary derivation by sigma-rectum pouch at the urology department of Smederevo. *Acta Chir Jugosl.* 2007;54(4):69-72.
36. Ladjevic N, Likic-Ladjevic I, Dzamic Z, Acimovic M, Dragicevic D, Durutovic O: Combined general and epidural anesthesia versus general anesthesia for radical cystectomy. *Acta Chir Jugosl.* 2007;54(4):89-92.
37. Janicic A, Tulic C, Radosevic-Jelic Lj, Dzamic Z, Acimovic M, Hadzi-Djokic J: Chemotherapy by M-VAC protocol in progressive bladder carcinoma treatment. *Acta Chir Jugosl.* 2007;54(4):97-100.

38. Radosavljevic R, Hadzi-Djokic J, Acimovic M, Pejic T, Tulic C, Dzamic Z: Morphologic characteristics of the urothelial bladder tumors. *Acta Chir Jugosl.* 2007;54(4):101-104.
39. Pejic T, Hadzi-Djokic J, Markovic B, Maksimovic H, Acimovic M, Milkovic B: Stage T2 prostate cancer presented with high serum prostate specific antigen and nonspecific bone lesions. *Acta Chir Jugosl.* 2007;54(4):109-113.
40. Hadzi-Djokic J, Pejic T, Vuksanovic A, Acimovic M, Dzamic Z: Orthotopic neobladder a 22 year experience. *Acta Chir Jugosl.* 2007;54(4):33-36.
41. Hadzi-Djokić J, Pejić T, Aćimović M, Andrejević V, Radosavljević R. Penile metastasis from invasive bladder cancer. *Acta Chir Jugosl.* 2009;56(2):101-3.
42. Pejić T, Hadzi-Djokić J, Marković B, Dragičević D, Glisić B, Lalić N, Aćimović M, Dzamić Z, Radosavljevic R. Urinary PSA level and relative tumor volume after prostate biopsy. *Acta Chir Jugosl.* 2009;56(2):17-21.
43. Hadzi-Djokić J, Pejić T, Colović V, Petrović M, Stamenković V, Aćimović M, Stanić M. Radical perineal prostatectomy. *Acta Chir Jugosl.* 2010;57(3):111-3.
44. Hadzi-Djokić J, Pejić T, Aćimović M, Andrejević V. The case of cavernous testicular hemangioma. *Acta Chir Jugosl.* 2010;57(2):107-9.
45. Jovanovic M, Vuksanović A, Dzamić Z, Aćimović M, Radovanović M, Djurasić L. Usage of a Trans-Obturator-Tape (T.O.T.) "outside-in" approach in surgical treatment of female stress urinary incontinence. *Acta Chir Jugosl.* 2011;58(1):99-102.
46. Petrović M, Andrejević V, Aćimović M, Djurasić L, Pejić T, Dzamić Z, Hadzi-Djokić J. Gigantic transitional cell carcinoma of the renal pelvis in the region of endemic nephropathy. *Acta Chir Jugosl.* 2012;59(3):105-7.
47. Blagojević-Lazić R, Radivojević D, Andrejević V, Dzamić Z, Acimović M, Milutinović D, Djurasić L, Hadzi-Djokić J. Malignant disease in renal transplant recipients-our experience. *Acta Chir Jugosl.* 2012;59(1):49-51.

48. Petrović M, Andrejević V, Djurasić L, Stamenković V, Acimović M, Pejčić T, Dragoslav B, Hadzi-Djokić J. Tumors of the horseshoe kidney-characteristics and literature review. *Acta Chir Jugosl.* 2012;59(1):53-5.
49. Hadzi-Djokić J, Andrejević V, Djurasić L, Acimović M, Petrović M, Pejčić T, Dzamić Z. Simultaneous ipsilateral testicular seminoma with pelvic ectopy and hematovesicula seminalis. *Acta Chir Jugosl.* 2012;59(3):109-11.
50. Pejčić T, Dzamić Z, Dimitrijević V, Acimović M, Hadzi-Djokić J. The case of the diverticular bladder tumor treated with diverticulectomy. *Acta Chir Jugosl.* 2013;60(1):91-3.
51. Dzamić ZM, Kajmaković BM, Pejčić T, Milković B, Acimović M, Djurasić Lj, Djokić JH. Assessment of the degree of renal failure in patients undergoing ileal conduit as a form of urine derivation in relation to the type of ureteral insertion. *Acta Chir Jugosl.* 2013;60(1):53-60.
52. Kajmaković BM, Dzamić ZM, Pejčić T, Milković B, Acimović M, Djokić JH. Assessment of the degree of congestive changes in the upper urinary tract in patients undergoing ileal conduit as a form of urine derivation in relation to the type of ureteral insertion. *Acta Chir Jugosl.* 2013;60(3):17-24.
53. Hadzi-Djokić J, Andrejević V, Pejčić T, Djurasić L, Acimović M, Dzamić Z. Bilateral renal cell carcinoma with bilateral synchronous adrenal gland metastases - a case report. *Pol Przegl Chir.* 2014 Feb 1;86(2):97-9.
54. Hadži-Djokić J, Milojević B, Pejčić T, Acimović M, Stamenković V, Dzamić Z. Sigma-rectum pouch (Mainz Pouch II). *Acta Chir Jugosl.* 2014;61(1):29-34. Review
55. Jovanović M, Dzamić Z, Acimović M, Kajmaković B, Pejčić T. Usage of Green-Light HPS 180-W laser vaporisation for treatment of benign prostatic hyperplasia. *Acta Chir Jugosl.* 2014;61(1):57-6
56. Pejčić T, Dzamić Z, Acimović M, Kajmaković B, Hadzi-Djokić J. New and experimental techniques in the treatment of benign prostatic diseases. *Acta Chir Jugosl.* 2014;61(1):75-80. Review.

57. Kajmaković BM, Džamić ZM, Dragičević S, Aćimović M, Milojević B, Djokić JH. Diagnostic and therapeutic protocol in the treatment of hypo functional kidney. Acta Chir Jugosl. 2014;61(1):113-8.
58. Hadzi-Djokic J, Andrejevic V, Pejic T, Djurasic L, Acimovic M, Dzamic Z. Bilateral renal cell carcinoma with bilateral synchronous adrenal gland metastases - a case report .Pol Przegl Chir. 2014 Feb;86(2):97-9.
59. Hadzi-Djokic J, Pejic T, Acimovic M, Dzamic Z: Tuberculous Bladder Contracture Treated by Augmentation Ileocystoplasty. Current Urology, 2007;1:121-124.
60. Pejic T, Hadzi-Djokic J, Markovic B, Dzamic Z, Djurasic L, Acimovic M. Repeated endoscopic treatments of multiple recurrent ureteral tumors following 15-year-long history of bladder tumors in the patient from endemic nephropathy region. Cent European J Urol. 2013;66(3):292-5.

The main interests are oncological and reconstructive surgery.

Annually, 60 to 80 radical prostatectomies of laparoscopic and retropubic (locally advanced disease), 50 to 60 cystectomies with different urine derivations (ileal conduit, orthotopic ileal W bladder with afferent ileal part non detubularaized for implantation of ureter, Sygma rectum pouch with modification in terms of ureter implantation with afferent ileal part non detubularaized).

Annually 25 to 30 reconstruction of the anterior and posterior urethra (buccal mucosis, penile skin) or bladder neck (Y-V plasty).

Annually 20 to 30 implants of penile prostheses (mainly 3 pieces prosthesis) due to erectile dysfunction.

Annually 20 to 30 penile reconstruction due to Peyronie's disease by grafting with implantation of 3 component prostheses.

Annually 5 to 10 artefital sphincters due to urinary incontinence.


Annually 15 to 20 partial nephrectomies.

Annually 10 to 15 glans resurfacing due to penile cancer and 15 to 20 inguinal and pelvic lymphadenectomies with sartorius muscle interposition due to glans or vulva cancer.

Annually 5 to 10 vesicovaginal fistulas repair, transvaginal, Martius flap.

УНИВЕРЗИТЕТ ЦРНЕ ГОРЕ

Ул. Цетињска бр. 2
П. факс 99
81000 ПОДГОРИЦА
Ц Р Н А Г О Р А
Телефон: (020) 414-255
Факс: (020) 414-230
E-mail: rektor@ac.me



UNIVERSITY OF MONTENEGRO

Ul. Cetinjska br. 2
P.O. BOX 99
81 000 PODGORICA
M O N T E N E G R O
Phone: (+382) 20 414-255
Fax: (+382) 20 414-230
E-mail: rektor@ac.me

Број: 08-1742
Датум, 24.06.2015 г.

Ref: _____
Date, _____

Na osnovu člana 72 stav 2 Zakona o visokom obrazovanju (Službeni list Crne Gore br. 44/14) i člana 32 stav 1 tačka 9 Statuta Univerziteta Crne Gore, Senat Univerziteta Crne Gore, na sjednici održanoj 24. juna 2015. godine, donio je

**O D L U K U
O IZBORU U ZVANJE**

Dr **VLADIMIR TODOROVIĆ** bira se u akademsko zvanje **redovni profesor Univerziteta Crne Gore** za predmet: Osnovi kliničke onkologije na studijskom programu Medicina na Medicinskom fakultetu, na neodređeno vrijeme.

REKTOR


Prof. Radmila Vojvodić



BIOGRAFIJA

Prof. dr Vladimir Todorovic rođen je 1964. godine u Subotici gde je završio osnovno i srednje obrazovanje.

Medicinski fakultet završava 1990. godine u Novom Sadu. Specijalizaciju Interne medicine polaze 1996. godine u Klinickom Centru Srbije i Univerzitetu u Beogradu, a subspecijalizaciju iz Onkologije 1998. na Institutu za onkologiju i radiologiju kao i Univerzitetu u Beogradu. Zvanje Magistra medicinskih nauka dobija 1997., a Doktorsku disertaciju brani 2000. godine na Beogradskom Univerzitetu. Sledece godine je biran za Asistenta za predmet Onkologija Medicinskog fakulteta u Podgorici, a za docenta 2005. godine na Univerzitetu Crne Gore. Nakon toga do 2015. je bio vanredni profesor, a od te godine je redovnog profesora Univerzitet Crne Gore. Nakon staza i rada u Opstoj medicini dobija specijalizaciju iz Interne medicine i radi na Odeljenju Onkologije u Opstoj Bolnici u Subotici. Nakon završene subspecijalizacije 2000. godine dobija poziv Ministarstva zdravlja Crne Gore da radi kao kadar u Klinickom Centru. Reorganizacijom Klinickog centra i osnivanjem Klinike za onkologiju i radioterapiju imenom je za prvog Direktora Klinike 2000. Godine. U periodu od 2012. do 2015. obavljao je funkciju Nacelnika Odeljenja hemioterapije. Sada se nalazi na poziciji Direktora Klinike za onkologiju i radioterapiju u Klinickom Centru Crne Gore. Prof. Dr Todorovic nacionalni je predstavnik Crne Gore u ESMO (Evropsko udruzenje medikalnih onkologa) od 2006. Takodje ima titulu ESMO Ambasadora. Clan je Borda direktora Mediteranskog udruzenja onkologa AROME iz Pariza sa kojim je organizovao tri medjunarodna Kurasa iz Onkologije i dvije konsenzus konferencije koje imaju uticaj na regionalni razvoj dijagnostike i terapije karcinoma. Glavni je istrazivac za nekoliko klinickih studija sprovedenih u Klinickom Centru. Objavio je vise radova kao autor i koautor u casopisima na SCI listi i drugim eminentnim zurnalima. Sa saradnicima je autor udzbenika za studente Medicinskog fakulteta u Podgorici za predmet Onkologija „ Osnove klinicke onkologije i palijativna nega“.

Oženjen je i ima dvije cerke

2020	SCI, SCIE, SSCI, A&HCI	Belkacemi Y, Grellier N, Ghith S, Debbi K, Coraggio G, Bounedjar A, Samlali R, Tsoutsou PG, Ozsahin M, Chauvet MP, Turkan S, Boussem H, Kuten A, Tesanovic D, Errihani H, Benna F, Bouzid K, Idbaih A, Mokhtari K, Popovic L, Spano JP, Lotz JP, Cherif A, To H, Kovcin V, Arsovski O, Beslija S, Dzodic R, Markovic I, Vasovic S, Stamatovic L, Radosavljevic D, Radulovic S, Vrbanec D, Sahraoui S, Vasev N, Stojkovski I, Risteski M, Freixa SV, Krengli M, Radosevic N, Mustacchi G, Filipovic M, Kerrou K, Taghian AG, Todorovic V, Geara F, Gligorov J.	1. A review of the international early recommendations for departments organization and cancer management priorities during the global COVID-19 pandemic: applicability in low- and middle-income countries.	Eur J Cancer
2020	SCI, SCIE, SSCI, A&HCI	Feng Du, Wenmiao Wang, Yongsheng Wang, Ming Li, Anjie Zhu, Jiayu Wang, Ruigang Cai, Fei Ma, Ying Fan, Qing Li, Pin Zhang, Vladimir Todorovic, Peng Yuan & Binghe Xu	Carboplatin plus taxanes are non-inferior to epirubicin plus cyclophosphamide followed by taxanes as adjuvant chemotherapy for early triple-negative breast cancer	Breast Cancer Res Treat
2019	SCI, SCIE, SSCI, A&HCI	EDUARD VRDOLJAK, GYORGY BODOKY, JACEK JASSEM, RAZVAN POPESCU, ROBERT PIRKER, TANJA ČUFER, SEMIR BEŠLIJA, ALEXANDRU ENIU, VLADIMIR TODOROVIĆ, KATERINA KOPECKOVÁ, GALIA KURTEVA, ZORICA TOMAŠEVIĆ, AGIM SALLAKU, SNEZHANA SMICHKOSKA, ŽARKO BAJIĆ, BRANIMIR SIKIC	Expenditures on Oncology Drugs and Cancer Mortality-to-Incidence Ratio in Central and Eastern Europe	Oncologist
2017	SCI, SCIE, SSCI, A&HCI	Vladimir Todorovic, Nada Cicmil Saric, Jadranka Lakicevic, Milan Sorat	Evaluation of safety of bevacizumab as second-line treatment of patients with metastatic colorectal cancer	JOURNAL OF BUON
2017	SCI, SCIE, SSCI, A&HCI	Gligorov J, Richard S, Todorovic V	New anti-HER2 agents: from second-generation tyrosine kinases inhibitors to bifunctional antibodies	Curr Opin Oncol
2017	SCI, SCIE, SSCI, A&HCI	Kandolf Sekulovic L, Peris K, Hauschild A, Stratigos A, Grob JJ, Nathan P, Dummer R, Forsea AM, Hoeller C, Gogas H, Demidov L, Lebbe C, Blank C, Olah J, Bastholt L, Herceg D, Neyns B, Vieira R, Hansson J, Rutkowski P, Krajsova	More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments	Eur J Cancer

		I, Bylaite-Bucinskiene M, Zalaudek I, Maric-Brozic J, Babovic N, Banjin M, Putnik K, Weinlich G, Todorovic V, Kirov K, Ocvirk J, Zhukavets A, Kukushkina M, De La Cruz Merino L, Ymeri A, Risteski M, Garbe C		
2016	SCI, SCIE, SSCI, A&HCI	Vrdoljak E, Bodoky G, Jassem J, Popescu RA, Mardiak J, Pirker R, Čufer T, Bešlija S, Eniu A, Todorović V, Kubáčková K, Kurteva G, Tomašević Z, Sallaku A, Smichkoska S, Bajić Ž, Šikić BI	Cancer Control in Central and Eastern Europe: Current Situation and Recommendations for Improvement	Oncologist
2014	SCI, SCIE, SSCI, A&HCI	Todorović, V., Damjanović, S. & Lukovac Janjić, N.	Targeted therapy in metastatic hereditary Paragangliomas	Mitteilungen Klosterneuburg
2014	SCI, SCIE, SSCI, A&HCI	Todorović, V.	Prevention and management of stomatitis during treatment with Everolimus	Wulfenia
2011	SCI, SCIE, SSCI, A&HCI	Vrdoljak, E., Wojtukiewicz, MZ., Pienkowski, T., Bodoky, G., Berzinec, P., Finek, J., Todorović, V., Borojević, N., Croitoru, A. & South Eastern European Research Oncology Group	Cancer epidemiology in Central and South Eastern European countries	Croatian Medical Journal